Full text is available at the source.
Glycaemic changes during early semaglutide treatment: a case of pancreatic adenocarcinoma
Blood sugar changes during early treatment with semaglutide in pancreatic cancer
AI simplified
Abstract
A 55-year-old woman experienced increased fasting plasma glucose from 107 mg/dL to 169 mg/dL after one month of semaglutide treatment despite a 4 kg weight loss.
- Initial glycated hemoglobin was 6.0%, which increased to 6.6% after treatment.
- Latent autoimmune diabetes in adults was ruled out by negative autoantibodies and preserved C-peptide levels.
- Carbohydrate antigen 19-9 levels were markedly elevated.
- Magnetic resonance imaging of the pancreas revealed a 4 × 3 cm irregular mass.
- Surgical exploration confirmed liver metastases and a diagnosis of metastatic pancreatobiliary adenocarcinoma.
- Atypical glycaemic changes during early treatment with semaglutide should be interpreted cautiously.
AI simplified